References

tumors

Malignant tumours

2224-50572587-6813

Rosoncoweb

10.18027/2224-5057-2025-036

tumors-1450

Research Article

КОНСЕНСУС

CONSENSUS

Российский консенсус по профилактике, диагностике и лечению рака желудка. Вопросы лекарственной терапии

Russian consensus on prevention, diagnosis and treatment of gastric cancer. Systemic therapy issues

https://orcid.org/0000-0001-7728-9533

Артамонова

Е. В.

Artamonova

E. V.

Елена Владимировна Артамонова

115478 Москва, Каширское шоссе, 23

Elena Vladimirovna Artamonova

23 Kashirskoe Shosse, Moscow 115478

https://orcid.org/0000-0002-1693-0523

Бесова

Н. С.

Besova

N. S.

Наталия Сергеевна Бесова

115478 Москва, Каширское шоссе, 23

Nataliya Sergeevna Besova

23 Kashirskoe Shosse, Moscow 115478

https://orcid.org/0000-0003-4879-2687

Болотина

Л. В.

Bolotina

L. V.

Лариса Владимировна Болотина

125284 Москва, 2-й Боткинский пр-д, 3

Larisa Vladimirovna Bolotina

3 2nd Botkinskiy proezd, Moscow 125284

https://orcid.org/0000-0002-4822-5044

Владимирова

Л. Ю.

Vladimirova

L. Yu.

Любовь Юрьевна Владимирова

344037 Ростов-наДону, 14-я линия, 63

Lyubov Yurevna Vladimirova

63 14 liniya St., Rostov-on-Don 344037

https://orcid.org/0000-0003-4848-6938

Жукова

Л. Г.

Zhukova

L. G.

Людмила Григорьевна Жукова

111123 Москва, Новогиреевская ул., 1, корп. 1

Lyudmila Grigorevna Zhukova

Build. 1, 1 Novogireevskaya St., Moscow 111123

https://orcid.org/0000-0002-8114-7885

Игнатова

Е. О.

Ignatova

E. O.

Екатерина Олеговна Игнатова

115478 Москва, Каширское шоссе, 23

Ekaterina Olegovna Ignatova

23 Kashirskoe Shosse, Moscow 115478

https://orcid.org/0000-0001-9431-5617

Моисеенко

В. М.

Moiseenko

V. M.

Владимир Михайлович Моисеенко

197758 Санкт-Петербург, пос. Песочный, Ленинградская ул., 68А, лит. А

Vladimir Mikhailovich Moiseenko

lit. A, 68A Leningradskaya St., Pesochnyy, Saint Petersburg 197758

https://orcid.org/0000-0001-9864-3837

Покатаев

И. А.

Pokataev

I. A.

Илья Анатольевич Покатаев

115478 Москва, Каширское шоссе, 23

Ilya Anatolevich Pokataev

23 Kashirskoe Shosse, Moscow 115478

https://orcid.org/0000-0001-5543-199X

Семенов

Н. Е.

Semenov

N. E.

Николай Евгеньевич Семенов

111123 Москва, Новогиреевская ул., 1, корп. 1

Nikolai Evgenevich Semenov

Build. 1, 1 Novogireevskaya St., Moscow 111123

n.semenov@mknc.ru

https://orcid.org/0000-0003-1973-1092

Строяковский

Д. Л.

Stroyakovskii

D. L.

Даниил Львович Строяковский

143515 Московская область, п. Истра, 27

Daniil Lvovich Stroyakovskii

27 Istra, Moscow Region 143515

https://orcid.org/0000-0003-2245-214X

Трякин

А. А.

Tryakin

A. A.

Алексей Александрович Трякин

115478 Москва, Каширское шоссе, 23

Aleksei Aleksandrovich Tryakin

23 Kashirskoe Shosse, Moscow 115478

https://orcid.org/0000-0001-9807-2229

Тюляндин

С. А.

Tyulyandin

S. A.

Сергей Алексеевич Тюляндин

115478 Москва, Каширское шоссе, 23

Sergei Alekseevich Tyulyandin

23 Kashirskoe Shosse, Moscow 115478

https://orcid.org/0000-0003-4927-5585

Феденко

А. А.

Fedenko

A. A.

Александр Александрович Феденко

125284 Москва, 2-й Боткинский пр-д, 3

Aleksandr Aleksandrovich Fedenko

3 2nd Botkinskiy proezd, Moscow 125284

https://orcid.org/0000-0001-5615-7806

Федянин

М. Ю.

Fedyanin

M. Yu.

Михаил Юрьевич Федянин

115478 Москва, Каширское шоссе, 23

Mikhail Yurevich Fedyanin

23 Kashirskoe Shosse, Moscow 115478

https://orcid.org/0000-0003-4533-1658

Шевкунов

Л. Н.

Shevkunov

L. N.

Лев Николаевич Шевкунов

197758 Санкт-Петербург, п. Песочный, ул. Ленинградская, 68

Lev Nikolaevich Shevkunov

68 Leningradskaya St., Pesochnyy, Saint Petersburg 197758

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияN. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaRussian Federation

Московский научно-исследовательский онкологический институт им. П.А. Герцена — филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииРоссияP. A. Hertsen Moscow Oncology Research Institute — branch of the National Medical Research Radiological Center, Ministry of Health of RussiaRussian Federation

ФГБУ «Национальный медицинский исследовательский центр онкологии» Минздрава РоссииРоссияNational Medical Research Centre for OncologyRussian Federation

ГБУЗ г. Москвы «Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения г. Москвы»РоссияA. S. Loginov Moscow Clinical Scientific Center, Moscow Healthcare DepartmentRussian Federation

БУЗ «Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический) им. Н.П. Напалкова»РоссияN. P. Napalkov Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)Russian Federation

ГБУЗ г. Москвы «Московская городская онкологическая больница No 62 Департамента здравоохранения г. Москвы»РоссияMoscow City Oncology Hospital No. 62, Moscow Healthcare DepartmentRussian Federation

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава РоссииРоссияN. N. Petrov National Medical Research Center of Oncology, Ministry of Health of RussiaRussian Federation

2025

15042025

151

76–85

Copyright © Артамонова Е.В., Бесова Н.С., Болотина Л.В., Владимирова Л.Ю., Жукова Л.Г., Игнатова Е.О., Моисеенко В.М., Покатаев И.А., Семенов Н.Е., Строяковский Д.Л., Трякин А.А., Тюляндин С.А., Феденко А.А., Федянин М.Ю., Шевкунов Л.Н., 2025

2025

Артамонова Е.В., Бесова Н.С., Болотина Л.В., Владимирова Л.Ю., Жукова Л.Г., Игнатова Е.О., Моисеенко В.М., Покатаев И.А., Семенов Н.Е., Строяковский Д.Л., Трякин А.А., Тюляндин С.А., Феденко А.А., Федянин М.Ю., Шевкунов Л.Н.

Artamonova E.V., Besova N.S., Bolotina L.V., Vladimirova L.Y., Zhukova L.G., Ignatova E.O., Moiseenko V.M., Pokataev I.A., Semenov N.E., Stroyakovskii D.L., Tryakin A.A., Tyulyandin S.A., Fedenko A.A., Fedyanin M.Y., Shevkunov L.N.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.malignanttumors.org/jour/article/view/1450

Российский консенсус по профилактике, диагностике и лечению рака желудка подготовлен по инициативе Московского клинического научного центра им А. С. Логинова ДЗМ по Дельфийской системе. Его целью явилась консолидация мнений отечественных специалистов по наиболее актуальным вопросам профилактики, скрининга, диагностики и лечения рака желудка. Междисциплинарный подход обеспечен участием ведущих гастроэнтерологов, онкологов и хирургов. В данной статье представлены ключевые нерешенные вопросы лекарственного лечения рака желудка, а также позиции Российского консенсуса по ним.

The Russian consensus on prevention, diagnostic and treatment of gastric cancer was prepared on the initiative of the Moscow clinical scientific center named after A. S. Loginov on the Delphi method. Its aim was to clarify and consolidate the opinions of specialists on the most relevant issues of prevention, diagnosis and treatment of gastric cancer. An interdisciplinary approach was provided by the participation of leading gastroenterologists, oncologists and surgeons.

консенсусрак желудкалекарственное лечение рака желудкасистемная химиотерапия

consensusgastric cancersystemic therapy

References1

Smyth E.C., Verheij M., Allum W., et al. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(suppl 5):v38-v49. https://doi.org/10.1093/annonc/mdw350

Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 2021;24(1):1–21. https://doi.org/10.1007/s10120-020-01041-y

NCCN Clinical Practice Guideline for Gastric Cancer version 3.2020. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf

Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer 2019;19(1):1–48. doi: 10.5230/jgc.2019.19.e8. Epub 2019 Mar 19. Erratum in: J Gastric Cancer 2019 Sep;19(3):372–373

Polom K., Marano L., Marrelli D., et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg 2018;105(3):159–167. https://doi.org/10.1002/bjs.10663

Kim S.Y., Choi Y.Y., An J.Y., et al. The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses. Int J Cancer 2015;137(4):819–25. https://doi.org/10.1002/ijc.29449

Pietrantonio F., Miceli R., Raimondi A., et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol 2019;37(35):3392–3400. https://doi.org/10.1200/JCO.19.01124

André T., Tougeron D., Piessen G., et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol 2023;41(2):255–265. https://doi.org/10.1200/JCO.22.00686

Pietrantonio F., Raimondi A., Lonardi S., et al. INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). J Clin Oncol 2023;41(4): suppl 358. https://doi.org/10.1200/JCO.2023.41.4_suppl.358

Lorenzen S., Götze T.O., Thuss-Patience P., et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II/III DANTE/IKF-s633 trial. J Clin Oncol 2024;42(4):410–420. https://doi.org/10.1200/JCO.23.00975

Sun H., Moiseyenko V., Chubenko V., et al. Neoadjuvant chemo-immunotherapy in mismatch repair deficient (dMMR)/ microsatellite instability (MSI) gastric carcinoma (GC): A multicenter retrospective study. Ann Oncol 2024;35(suppl_2):S180-S181. https://doi.org/10.1016/j.annonc.2024.05.362

Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24(31):4991–7. https://doi.org/10.1200/JCO.2006.06.8429

Wang J., Xu R., Li J., et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer 2016;19(1):234–44. https://doi.org/10.1007/s10120-015-0457-4

Yamada Y., Boku N., Mizusawa J., et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2019;4(7):501–510. https://doi.org/10.1016/S2468-1253(19)30083-4

Guo X., Zhao F., Ma X., et al. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer 2019;19(1):1125. https://doi.org/10.1186/s12885-019-6294-9

Zaanan A., Bouche O., de la Fouchardiere C., et al. LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD. Ann Oncol 2023;34(suppl_2):S1254-S1335. https://doi.org/10.1016/S0923-7534(23)04149-2

Ramaswamy A., Bhargava P., Dubashi B., et al. A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/5 fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers (DOC-GC study). J Clin Oncol 2024;42(3_suppl): LBA248-LBA248. https://doi.org/10.1200/JCO.2024.42.3_suppl.LBA248

Messager M., Lefevre J.H., Pichot-Delahaye V., et al. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg 2011;254(5):684–93; https://doi.org/10.1097/SLA.0b013e3182352647

Sasako M., Sakuramoto S., Katai H., et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29(33):4387–93. https://doi.org/10.1200/JCO.2011.36.5908

Noh S.H., Park S.R., Yang H.K., et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15(12):1389–96. https://doi.org/10.1016/S1470-2045(14)70473-5

Kozak K.R., Moody J.S. The survival impact of the intergroup 0116 trial on patients with gastric cancer. Int J Radiat Oncol Biol Phys 2008;72(2):517–21. https://doi.org/10.1016/j.ijrobp.2007.12.029

Ychou M., Boige V., Pignon J.P., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29(13):1715–21. https://doi.org/10.1200/JCO.2010.33.0597

Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355(1):11–20. https://doi.org/10.1056/NEJMoa055531

Al-Batran S.E., Homann N., Pauligk C., et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393(10184):1948–1957. https://doi.org/10.1016/S0140-6736(18)32557-1

Lutz M.P., Zalcberg J.R., Ducreux M., et al. The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. Eur J Cancer 2019;112:1–8. https://doi.org/10.1016/j.ejca.2019.01.106

Yoshida K., Kodera Y., Kochi M., et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol 2019;37(15):1296–1304. https://doi.org/10.1200/JCO.18.01138

Park S.H., Zang D.Y., Han B., et al. ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/ or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC). J Clin Oncol 2019;37(15_suppl):4001. https://doi.org/10.1200/jco.2019.37.15_suppl.4001

Allum W.H., Stenning S.P., Bancewicz J., et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27(30):5062–5067. https://doi.org/10.1200/JCO.2009.22.2083

Al-Batran S. E, Homann N, Pauligk C., et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393(10184):1948–1957. https://doi.org/10.1016/S0140-6736(18)32557-1

Van den Ende T., Veer E.T., Machiels M., et al. The efficacy and safety of (Neo)adjuvant therapy for gastric cancer: a network meta-analysis. Cancers (Basel) 2019;11(1):80. https://doi.org/10.3390/cancers11010080

Trumper M., Ross P.J., Cunningham D., et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. Eur J Cancer 2006;42(7):827–34. https://doi.org/10.1016/j.ejca.2005.08.044

Jatoi A., Foster N.R., Egner J.R., et al. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. Int J Oncol 2010;36(3):601–6. https://doi.org/10.3892/ijo_00000535

Hall P.S., Lord S.R., Collinson M., et al. A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). Br J Cancer 2017;116(4):472–478. https://doi.org/10.1038/bjc.2016.442

Hwang I.G., Ji J.H., Kang J.H., et al. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. J Geriatr Oncol 2017;8(3):170–175. https://doi.org/10.1016/j.jgo.2017.01.002

Hall P.S., Swinson D., Cairns D.A., et al. Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 phase 3 randomized clinical trial. JAMA Oncol 2021;7(6):869–877. https://doi.org/10.1001/jamaoncol.2021.0848

Thuss-Patience P.C., Kretzschmar A., Bichev D., et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47(15):2306–14. https://doi.org/10.1016/j.ejca.2011.06.002

Ford H.E., Marshall A., Bridgewater J.A., et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014;15(1):78–86. https://doi.org/10.1016/S1470-2045(13)70549-7

Hironaka S., Ueda S., Yasui H., et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013;31(35):4438–44. https://doi.org/10.1200/JCO.2012.48.5805

Wilke H., Muro K., Van Cutsem E., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15(11):1224–1235. https://doi.org/10.1016/S1470-2045(14)70420-6

Kaya A.O., Coskun U., Gumus M., et al. The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens. J Chemother 2012;24(4):217–20. https://doi.org/10.1179/1973947812Y.0000000020

Maugeri-Saccà M., Pizzuti L., Sergi D., et al. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. J Exp Clin Cancer Res 2013;32(1):67. https://doi.org/10.1186/1756-9966-32-67

Sendur M.A., Ozdemir N., Özatlı T., et al. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen. Med Oncol 2014;31(9):153. https://doi.org/10.1007/s12032-014-0153-y

Jung J.Y., Ryu M.H., Ryoo B.Y., et al. Second-line irinotecan, leucovorin, and 5-fluorouracil for gastric cancer patients after failed docetaxel and S-1. Gastroenterol Res Pract 2016;2016:6857625. https://doi.org/10.1155/2016/6857625

Klempner S.J., Maron S.B., Chase L., et al. Initial report of second-line FOLFIRI in combination with ramucirumab in advanced gastroesophageal adenocarcinomas: a multi-institutional retrospective analysis. Oncologist 2019;24(4):475–482. https://doi.org/10.1634/theoncologist.2018-0602

Бесова Н.С., Титова Т.А., Строяковский Д.Л. и соавт. Результаты применения рамуцирумаба с иринотеканом и фторпиримидинами во второй линии лечения больных диссеминированным раком желудка. Медицинский совет 2019;10:100–109. https://doi.org/10.21518/2079-701X-2019-10-100-109

Besova N.S., Titova T.A., Stroyakovsky D.L., et al. Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer. Meditsinsky Sovet 2019;10:100–109 (In Russ.). https://doi.org/10.21518/2079-701X-2019-10-100-109

Lorenzen S., Thuss-Patiens P., Pauligk C., et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: Interim safety and efficacy results from the phase II RAMIRIS Study (AIO-STO-0415) of the German Gastric Group at AIO. Journal of Clinical Oncology 38(15_suppl):4514–4514. https://doi.org/10.1200/JCO.2020.38.15suppl.4514

Sym S.J., Hong J., Park J., et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol 2013;71(2):481–8. https://doi.org/10.1007/s00280-012-2027-3

Tanabe K., Fujii M., Nishikawa K., et al. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05). Ann Oncol 2015;26(9):1916–1922. https://doi.org/10.1093/annonc/mdv265

Shitara K., Özgüroğlu M., Bang Y.J., et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018;392(10142):123–133. https://doi.org/10.1016/S0140-6736(18)31257-1

Chao J., Fuchs C.S., Shitara K., et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol 2021;7(6):895–902. https://doi.org/10.1001/jamaoncol.2021.0275.

The authors declare that there are no conflicts of interest present.